This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas

This study has been terminated.
(Poor enrollment)
EMD Serono
Genentech, Inc.
Information provided by:
Columbia University Identifier:
First received: March 25, 2008
Last updated: April 22, 2011
Last verified: April 2011
The purpose of this study is to determine if patients with a history of nonsecreting pituitary adenomas with untreated GH deficient patients have profiles consistent with increased cardiovascular risk compared to patients without GH deficiency who have undergone similar surgery.

Growth Hormone Deficiency Pituitary Tumor

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Assessment of Cardiovascular Risk Markers in GH Deficient Patients With Nonsecreting Pituitary Adenomas

Resource links provided by NLM:

Further study details as provided by Columbia University:

Primary Outcome Measures:
  • Cardiovascular risk markers, specifically lipids, CRP, IL6 and homocysteine [ Time Frame: One time point ]

Secondary Outcome Measures:
  • Total body fat, trunk fat and lean body mass by DEXA, insulin sensitivity, flow mediated dilatation and endothelial cell biopsy, carotid IMT, intramyocellular and intrahepatic lipid content. [ Time Frame: One time point ]

Biospecimen Retention:   None Retained
Serum samples

Estimated Enrollment: 60
Study Start Date: March 2008
Study Completion Date: March 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Adult patients with GH deficiency due to a nonsecreting pituitary tumor
Adult patients with a nonsecreting pituitary tumor but without GH deficiency

  Show Detailed Description


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult patients with a history of nonsecreting pituitary tumor.

Inclusion Criteria:

  • Adult patients with a history of a nonsecreting pituitary tumor with or without prior pituitary surgery.

Exclusion Criteria:

  • Current use of GH therapy or within the prior 3 months. Pituitary tumor necessitating surgery.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00646308

United States, New York
Columbia University Neuroendocrine Unit
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
EMD Serono
Genentech, Inc.
Principal Investigator: Pamela U Freda, MD Columbia University College of P & S
  More Information

Responsible Party: Pamela U. Freda MD, Columbia Univesrity Identifier: NCT00646308     History of Changes
Other Study ID Numbers: AAAB9681
Study First Received: March 25, 2008
Last Updated: April 22, 2011

Keywords provided by Columbia University:
growth hormone deficiency, pituitary tumors

Additional relevant MeSH terms:
Pituitary Diseases
Dwarfism, Pituitary
Pituitary Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Endocrine Gland Neoplasms
Neoplasms by Site
Hypothalamic Neoplasms
Supratentorial Neoplasms
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Endocrine System Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Bone Diseases, Endocrine
Hypopituitarism processed this record on September 21, 2017